Original Research Article

Complement-mediated killing of *Leishmania martiniquensis* promastigotes

Abstract

Background: Leishmaniasis caused by various species is now an emerging autochthonous disease. *L. martiniquensis was* described first from a human case in Martinique island and to date is frequently causing human infections in many countries. To eliminate the invading pathogen, complement activation of the innate system plays an effectiveness role of host's defense. This study aims to test the parasiticidal activity of the complement activation against *L. martiniquensis* promastigotes.

Methods: An in vitro examination of parasite mortality rate incubated in fresh normal human serum (NHS) was performed compared to heat-inactivated, and ion chelated sera.

Results: We observed a lethal effect on the parasite when exposed to fresh NHS. Our parasites when tested with heat-inactivated at 56 ^{0}C for 30 min and ethylene diamine tetra acetic acid (EDTA) chelated sera indicated complement dependent parasiticidal activity. Ethyleneglycol tetraacetic acid (EGTA) chelated, and EDTA+MgCl$_2$ treated sera demonstrated that *L. martiniquensis* promastigotes activated the complement via alternative pathway. This pathway was also revealed when the parasite was subjected to zymosan treated sera and that of the heat inactivated (50 ^{0}C for 15 min). Interestingly, positive mannose-binding lectin (MBL) of the parasite surfaces demonstrated by using anti- MBL antibody immunofluorescent test.

Conclusion: The parasitical activity is antibody independent mediated via the alternative pathway. The involvement of MBL could not exclude. These preliminary data might provide a further study for explanation of the anatomic sequestration or immune evasion strategy of the *Leishmania* species.

Key-words: Complement, *Leishmania martiniquensis*; Promastigote, Alternative pathway, Mannose-binding lectin

Introduction

Leishmaniasis is caused by parasites belonging to the genus *Leishmania* [1]. More than 20 species have been determined as human pathogens which endemic in many countries, including, the Middle East, Central and North America, Indian subcontinent, and Mediterranean basins [1]. The parasites have a digenetic life cycle, composed of the vertebrate host (amastigote stage) and an insect vector (promastigote stage) [2]. The disease is transmitted to vertebrate hosts by the bite (intradermal inoculation of the promastigote) of an infected female sandfly [3]. *L. martiniquensis*, firstly discovered on Martinique Island, is now the cause of autochthonous disease in the majority of cases of many countries [4,5]. Clinical presentation of this species infection includes diffuse cutaneous, visceral, and overlapping diffuse cutaneous and visceral forms [6,7]. The infected cases are mostly found in immuno-compromised patients [8]. Innate response principally plays an important first line against pathogens. A number of studies showed lethal effect on various pathogens which depend upon the complement activation by forming the membrane attack complex (MAC) and promoting an inflammatory reaction. [9,10]. There are three major pathways of the complement system: classical, alternative and

lectin. Binding of antibodies to the parasites will initiate the classical pathway, while the binding of mannose-binding lectin (MBL) can activate the lectin pathway. An alternative pathway can be directly activated by the pathogen's molecule [11]. *Leishmania* stays inside the host cell in form of amastigote might be the manner for escaping complement attack, as a survival strategy and propagation is not well understood [12]. Humoral factor of the complement system showed lethal effect on many species includes *L. major*, *L. mexican*, *L. chagasi*, *L. infantum*, and others [13]. In vitro of those studies, more than 80% of the promastigotes exhibited lysis within minutes of time after being cultured with fresh normal human sera (NHS). The process was mediated by the alternative pathway of complement which antibody independent [13].

The present study examines lethal effect on *L. martiniquensis* promastigotes when incubated with fresh NHS, and various conditions of sera treatment. To destroy or inactivate all complement systems and have only the alternative pathway done, sera were heated at 56 ^{0}C, 30 min and 50 ^{0}C, 15 min. Serum treatment with divalent chelate ions of EDTA (calcium and magnesium chelating) to inactivation both classical and alternative pathways were used. In addition, those treated with EGTA (calcium chelating) to destroy only the classical pathway have also been studied. More testing is undertaken in zymosan treated serum because this polysaccharide composed primarily of glucan and mannan residues, can predominantly activate the complement system through the alternative complement pathway. The suspected MBL on our *L. martiniquensis* promastigotes surface was revealed by an anti-MBL immunofluorescence antibody test. Results obtained from this study may increase understanding of the host innate defense of the complement system, the parasite evasion strategies, and immuno-pathogenicity of the infection.

Materials and Methods

Ethics statement

The experimental procedures used in this study were approved by the Institutional Review Board of the Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand (COA No. 768/2012). Sera donors were explained for the purpose with written informed consent.

Parasite, sera, and chelating agents

L. martiniquensis promastigotes used were that from a leishmaniasis patient of southern Thailand (CU1 isolate) [14]. The parasites were cultured in Schneider's Insect Medium (Sigma-Aldrich, USA) at a pH of 6.7 supplemented with 10% heat-inactivated fetal bovine serum, 100 U/ml penicillin and 100 µg/ml streptomycin. The cells were maintained at $25\pm2\,^0C$ and inspected for viability every 24 h under an inverted microscope (Olympus, Japan). In this experiment stationary phase promastigotes were harvested by centrifugation (1,100xg at $20\,^0C$ for 10 min) and washed twice in 1x phosphate buffer saline (PBS) (Sigma-Aldrich, USA).

Sera donors have no history of leishmaniasis, and negative for Leishmanial antibody test. The blood was taken, allowed to clot at $4\,^0C$ for 2 h and subjected in a refrigerated centrifuge (400xg for 20 min). The decanted NHS was aliquoted and stored at $-80\,^0C$ until further uses.

Different chelating agents, EDTA (Sigma-Aldrich, USA) and EGTA (Sigma-Aldrich, USA) prepared as a stock solution of 12 mM. Mg++ ion in form of $MgCl_2$ (Sigma-Aldrich, USA) was provided at a concentration of 8 mM in order to add in the chelated sera for accession the requirement ion for alternative pathway process. Zymosan suspension (Sigma-Aldrich, USA) in PBS and boiled to sterilize was prepared. The concentration of the chelating agents and zymosan suspension use as described [15] were tested for viability prior to treat because high concentrations of the agents may directly affect the parasite.

Fresh NHS were mixed with chelating agent and zymosan (ratio 1:1), and incubated in 37 C for 30 min. The zymosan was removed out from the treated sera by centrifugation at 2,000 rpm for 30 min at 4 C. The pre-treated sera were all then centrifuged at 3,200 rpm for 20 min prior to use.

In vitro test for parasiticidal activity

The lethal effect on *L. martiniquensis* promastigotes (10^6 parasites/ml) was determined by reacting the with various condition/ treatment of the sera and incubated at 25 ± 2^0C in a plastic tissue culture plate (Corning, USA) at a ratio of 1:1 (volume by volume) for 15, 30, and 60 min.

Analysis of *L. martiniquensis* promastigotes killing was performed by gently mixing of 20 µl reacted promastigotes with 20 µl of trypan blue solution stock (Sigma-Aldrich, USA), and kept at room temperature for 5 min. Then, 10 µl of the cells were counted on a hemocytometer for the number of viable (unstained with trypan blue) and dead (stained with trypan blue) cells. Mortality rate in percentage was calculated.

Immunofluorescence analysis

An immunofluorescence test was performed to detect MBL on the parasite surface. Our cultured *L. martiniquensis promastigotes* with fresh NHS and 56^0C 30 min heated sera were smeared onto microscope slides, air-dried and fixed in 4% paraformaldehyde (Sigma-Aldrich, USA). The cells were permeabilized with 1xPBS containing 1% BSA and 0.1% Triton for 10 min. Slides were washed and reacted with rabbit monoclonal anti-MBL antibody (Abcam, Cambridge, UK) in PBS and tris-buffer containing 10% normal horse serum at concentration 1:500 for 2 h at room temperature. The slides were then incubated with a secondary antibody (goat anti-rabbit IgG fluorescence (Alexa fluor®488) (Abcam, Cambridge, UK) at a concentration of 1:1000 and left for 30 min before examination under a fluorescence microscope at 494 nm (Olympus, Japan).

Results

Incubation of *L. martiniquensis* promastigotes with fresh NHS exhibited the maximum killing of the parasite 74.0, 94.6 and 90.6%) at 15, 30, and 60 mins, respectively (Figure 1). This lethal effect of sera became undetectable by diluting the serum beyond 1:16. The effects were all significantly abrogated (5.6-5.8%) in heated serum (at $56\ ^0$C for 30 min) which indicated that the activity was heat labile, suggesting the involvement of complement in the process. Among the various complement components, factor B of the alternative pathway appeared to be more labile than others. The mortality rate of our parasite in $50\ ^0$C for 15 min heated sera showed significant decrease from 90.6% to 27.8% (at 60 mins) which was associated with the alternative pathway activation (Figure 1).

To obtain further evidence for supporting the above suggestion, our fresh NHS was then treated with chelating agent. All divalent cations including Ca++ and Mg++ would be chelated in EDTA treated sera, thus all the three pathways of complement activation are blocked. When EGTA was added to the serum, only Ca++ would be chelated and the alternative pathway which requires Mg++ could still be activated. In the experiment, alternative pathway activation was optimized by adding an extraneous source of Mg++ to the EDTA treated serum for essential ions providing.

In our study concentration of 6 mM of neither the EDTA nor EGTA had any effect when incubated with our promastigate. Four mM $MgCl_2$ added to the parasite culture medium also had no effect on our parasite survival. The fresh NHS was treated with EGTA at a final concentration of 6 mM to selectively chelate Ca^{2+}, thus stopping both the classical and MBL pathways activation, but not the alternative pathway which requires Mg ions. This did not subsequently decrease the parasiticidal activity, since the parasite was mostly killed in EGTA treated serum (78.2% mortality rate, (range 65-82% Table 1). The results indicating that the parasiticidal activity was inhibited in EDTA treated sera whereas most promastigotes were killed in EGTA treated sera, suggesting the involvement of alternative pathway in this process. The addition of $MgCl_2$ (4 mM) in EDTA chelated sera showed that *L. martiniquensis* promastigotes can activate the alternative complement pathway. (86.4% mortality rate, (range 78-95%) Table 1).

However, we confirmed the pathway by pretreatment of fresh NHS with zymosan. Zymosan is known to activate or consume complement predominantly via the alternative pathway. By incubating the promastigotes with this agent (40 mg/ml)

exhibited no effect on the parasite. In the experiment, the alternative depleted serum reduced percentage of the mortality (from 90.6 ± 2.3 to 47.8 ± 5.6%, Table1).


Fig. 1: Percentage of parasite mortality rate incubated with fresh normal human sera, heat-treated sera (56 ^{0}C 30 min) and (50 ^{0}C 15 min) against *L. martiniquensis* promastigotes at different time interval of 15, 30 and 60 mins

*, Fresh normal human serum is the untreated sera or control used in the system.

a b, Values within a row with different treatment are significantly different (P <0.01; T-test).

Table 1: Effect of chelating agents on parasiticidal activity of fresh normal human sera against *L. martiniquensis* promastigotes

Treatment of Fresh normal human sera	% Mortality at 60 min incubation	
	range	mean ± SE
Untreated**	85-97	96.6 ± 2.3
6 mM EDTA	28-40	32.6 ± 2.2[c]
6 mM EGTA	65-82	78.2 ± 3.6
6 mM EDTA + 4 mM MgCl$_2$	78-95	86.4 ± 3.1
40 mg/ml Zymosan	33-62	47.8 ± 5.6[c]

** Untreated is the control used in the system.

[c] Values within a column with different treatment are significantly different (P <0.01; T- test).

We observed the present of MBL on our promastigotes surface incubated with fresh NHS by immunofluorescence test using monoclonal anti-MBL antibody. Surface MBL-negative binding was detected when the parasite was cultured in heat-activated NHS (at 56 ^{0}C for 30 min) (Figure 2 A, B). In contrast, the anti-MBL antibody showed positive staining around the surface of the cell which exposed to fresh NHS (Figure 2 C, D).

Fig. 2: Bright-field microscopic images of immunofluorescence staining using an anti-MBL antibody (magnification 40x) for *L. martiniquensis* promastigotes incubated in heated NHS at 56 ^{0}C for 30 min (A, B) and fresh NHS (C, D)

Discussion

In this study, the data presented suggests that *L. martiniquensis* promastigotes can be readily killed when exposed to fresh NHS. The lethal effect of the serum is complement-dependent, since the activity was inhibited by heat inactivation (56 ^{0}C for 30 min) and by EDTA treatment. It is generally accepted that EDTA would chelate all divalent cations including Ca^{2+} and Mg^{2+}, thus all pathways of complement activation are blocked [11]. Only Ca^{2+} ions would be chelated by EGTA, thus the alternative pathways requiring Mg^{2+} ions would still be activated [11]. Parasite mortality is diminished by pre-treatment of the serum with either zymosan or anti-human factor B which indicated a proceeding activation of the alternative pathway. The selective factor B can be destroyed by heating the serum at 50 ^{0}C for

15 min. The activity can be restored by the addition of purified human factor B (data not shown). The involvement of the alternative pathway in these parasiticidal processes is strongly suggested.

The mechanism(s) by which this *L. martiniquensis* promastigote triggers a complement response via these innate factors is not known. Investigation for MBL of the surface demonstred positive using the immunofluorescence test. MBL is a well-known complement activator and an efficient opsonin. Binding and promoting lysis of live promastigotes of *L. braziliensis* by MBL were reported [16].

Results of our study show that the biological circumstance of the parasiticidal action in normal serum requires further study. It is tempting to theorize that this phenomenon may play a role in the natural host defense against this parasite. It may also explain anatomical sequestration of why the invading promastigotes from the invertebrate sand fly vector transform into amastigotes inside the mononuclear phagocytes which is likely the hosts' immune evasion [13]. The clinical outcome and severity reported of this disease greatly depends upon the species of *Leishmania* and the host immune situation [17,18]. Our results are the first to demonstrate the complement-mediated killing of the species *L. martiniquensis* promastigotes in vitro study. The results were compared to the treating/ chelating NHS which revealed that the parasiticidal activity depends upon the alternative pathway; an antibody independent process. This parasite killing process requires Mg^{2+} but not Ca^{2+} since the process was inhibited by zymosan treated sera which suggested an activation proceeds via an alternative pathway. However, the involvement of the MBL pathway might not exclude.

There is a question of which complement pathways are critical in resistance or clearance of *Leishmania* in the infected vertebrate host. An alternative complement

pathway is seen as the major essential pathway that can eliminate various species of the *Leishmania* pathogen [13]. *L. donovani* (the Sudan strain), *L. major* (strains 1-S and 252), *L. braziliensis guyanensis, L.* dependent of human serum and would activate the alternative complement pathway [13,19]. Complement mediated clearance of *L. tropica* and *L. enriettii* promastigotes by NHS was shown to be antibodies or C4 independent, but mediated by the alternative pathway following the formation of C5b-9 MAC [20,21]. The IgM antibody in *Leishmania* activated the complement by the classical pathway leading to promastigote agglutination and death as in *L. donovani* was reported [22-24]. *Leishmania* promastigotes that are covered by a surface protein such as the gp63 metalloproteinase, proteophosphoglycans (PPGs), abundant lipophosphoglycan (LPG), and the MBL have been showed [18,25].

Serum MBL binding of *L. braziliensis* promastigotes also suggested the possible contribution of the lectin pathway in the pathogen killing [16]. MBL is a calcium-dependent plasma lectin that can bind to various microorganisms. It has shown a strong association with the severity of microbial infections [12,26]. The binding of MBL by the pathogen could subsequently spur complement activation by increasing uptake of PMN (opsonophagocytosis) [11]. This process needs further research and observation for the species *L. martiniquensis*. It may explain the increased risk of these microorganism infections in MBL-deficient individuals [27]. Interestingly, there is report demonstrating that the level of MBL is directly associated with pathogenesis and the likelihood of developing visceral leishmaniasis upon *L. chagasi* infection [28,29]. The molecular mechanism for complement activation in the species *L. martiniquensis* in our study has not yet been fully described.

Conclusions

Data presented in this experiment suggested that *L. martiniquensis* promastigotes are readily killed following an exposure to fresh NHS. To the best of our knowledge, this is the first study examining alternative pathways and the presenting of surface MBL of this species of *L. martiniquensis* promastigotes. Future studies should focus attention on the important role of the complement system and interaction of the host and the parasite *L. martiniquensis* to help deepen our understanding of parasite evasion strategies, host immunity, and pathogenicity.

References

1.   Maxfield L, Crane JS. Leishmaniasis. Treasure Island (FL) : StatPearls Publishing. 2017. Accessed 5 September 2017. Available: https://www.ncbi.nlm.nih.gov/books/NBK430685/.

2.   Akhoundi M, Kuhls K, Cannet A, Votýpka J, Marty P, Delaunay P, Sereno D. A historical overview of the classification evolution and dispersion of Leishmania parasites and sandflies. PLOS Neglected Tropical Diseases. 2016; 3(3): e0004349. doi: 101371/journalpntd0004349

3.   Mhadhbi M, Sassi A. Infection of the equine population by Leishmania parasites. Equine Veterinary Journal. 2020;52(1): 28-33. doi: 101111/evj13178

4.   Jariyapan N, Daroontum T, Jaiwong K, Chanmol W, Intakhan N, Sor-Suwan S, Siriyasatien P, Somboon P, Bates MD, Bates PA. Leishmania (Mundinia) orientalis n sp (Trypanosomatidae) a parasite from Thailand responsible for

localised cutaneous leishmaniasis. Parasites and Vectors 2018;18(1):351. doi: 101186/s13071-018-2908-3

5. Pothirat T, Tantiworawit A, Chaiwarith R, Jariyapan N, Wannasan A, Siriyasatien P, Supparatpinyo K, Bates MD, Kwakye-Nuako G, Bates PA. First isolation of Leishmania from Northern Thailand: case report identification as Leishmania martiniquensis and phylogenetic position within the Leishmania enriettii complex. PLOS Neglected Tropical Diseases. 2014;4(12):e3339. doi: 101371/journalpntd0003339

6. Chusri S, Hortiwakul T, Silpapojakul K, Siriyasatien P. Consecutive cutaneous and visceral leishmaniasis manifestations involving a novel Leishmania species in two HIV patients in Thailand. American Journal of Tropical Medicine and Hygiene. 2012;87(1):76-80. doi: 104269/ajtmh201211-0749

7. Suankratay C, Suwanpimolkul G, Wilde H, Siriyasatien P. Autochthonous visceral leishmaniasis in a human immunodeficiency virus (HIV)-infected patient: the first in thailand and review of the literature. American Journal of Tropical Medicine and Hygiene. 2010;82(1):4-8. doi: 104269/ajtmh201009-0434

8. Leelayoova S, Siripattanapipong S, Manomat J, Piyaraj P, Tan-Ariya P, Bualert L, Mungthin M. Leishmaniasis in Thailand: A review of causative agents and situations. American Journal of Tropical Medicine and Hygiene. 201;796(3): 534-542. doi:104269/ajtmh16-0604

9. Abbas AK, Lichtman AH, Pillai S. Cellular and molecular immunology. 10th ed. San Francisco: Saunders Publishers; 2021.

10. Shao S, Sun X, Chen Y, Zhan B, Zhu X. Complement evasion: An effective strategy that parasites utilize to survive in the host. Frontiers in Microbiology 2019;20:532. doi: 103389/fmicb201900532

11. Bellanti JA. Immunology IV Clinical applications in health and disease. 4th ed. Washington DC: I Care Press; 2012.

12. Walker DM, Oghumu S, Gupta G, McGwire BS, Drew ME, Satoskar AR. Mechanisms of cellular invasion by intracellular parasites. Cellular and Molecular Life Sciences. 2014;71(7):1245-1263. doi: 101007/s00018-013-1491-1

13. Gurung P, Kanneganti TD. Innate immunity against Leishmania infections Cellular Microbiology. 2015;17(9):1286-1294. doi: 101111/cmi12484

14. Phumee A, Jariyapan N, Chusri S, Hortiwakul T, Mouri O, Gay F, Limpanasithikul W, Siriyasatien P. Determination of anti-leishmanial drugs efficacy against Leishmania martiniquensis using a colorimetric assay. Parasite Epidemiology and Control. 2020;19:e00143. doi: 101016/j parepi2020e00143

15. Sirisinha S, Rattanasiriwilai W, Puengtomwatanakul S, Sobhon P, Saitongdee P, Koonchornboon T, Complement-mediated killing of Opisthorchis viverrini via activation of the alternative pathway. International Journal for Parasitology. 1986;16(4):341-346.

16. Ambrosio AR, De Messias-Reason IJ. Leishmania (Viannia) braziliensis: interaction of mannose-binding lectin with surface glycoconjugates and complement activation An antibody-independent defence mechanism. Parasite Immunology. 2005;27(9):333-340. doi: 101111/j1365-3024200500782x

17. Maia CS, Monteiro MC, Gavioli EC, Oliveira FR, Oliveira GB, Romão PR. Neurological disease in human and canine leishmaniasis-clinical features and immunopathogenesis. Parasite Immunology. 2015; 37(8):385-393 doi: 101111/ pim 12203

18. Veras PST, Ramos PIP, de Menezes JPB. In search of biomarkers for pathogenesis and control of leishmaniasis by global analyses of Leishmania-infected macrophages. Frontiers in Cellular and Infection Microbiology. 2018;19;8(8):326. doi: 103389/fcimb201800326

19. Mosser DM, Burke SK, Coutavas EE, Wedgwood JF, Edelson PJ, Leishmania species: mechanisms of complement activation by five strains of promastigotes. Experimental Parasitology. 1986; 62(3):394-404. doi: 101016/ 0014-4894(86)90048-2

20. Hoover DL, Nacy CA, Macrophage activation to kill Leishmania tropica: defective intracellular killing of amastigotes by macrophages elicited with sterile inflammatory agents. Journal of Immunology. 1984;132(3):1487-1493.

21. Mosser DM, Edelson PJ. Activation of the alternative complement pathway by Leishmania promastigotes: parasite lysis and attachment to macrophages. Journal of Immunology. 1984;132(3):1501-1505.

22. Domínguez M, Toraño A. Immune adherence-mediated opsonophagocytosis: the mechanism of Leishmania infection. Journal of Experimental Medicine. 1999;4(1):25-35. doi: 101084/jem189125

23. Mendes APO, Oliveira BC, Pereira AMS, Castro MCAB, Souza MA, Brito MEF ,Araújo FF, Teixeira-Carvalho A, Martins-Filho OA, Pereira VRA. American tegumentary leishmaniasis diagnosis using L (V) braziliensis fixed promastigotes: a comparative performance of serological tests and

spontaneous cure identification. BMC Infectious Diseases. 2019;29(1):1015. doi: 101186/s12879-019-4642-7

24. Navin TR, Krug EC, Pearson RD. Effect of immunoglobulin M from normal human serum on Leishmania donovani promastigote agglutination complement-mediated killing and phagocytosis by human monocytes. Infection and Immunity. 1989;57(4):1343-1346. doi: 101128/IAI5741343-13461989

25. Yao C, Donelson JE, Wilson ME. The major surface protease (MSP or GP63) of Leishmania sp Biosynthesis regulation of expression and function. Molecular and Biochemical Parasitology. 2003;132(1):1-16. doi: 101016/s0166-6851(03) 00211-1

26. Shen W, Xiao L, Li Y, Zhou D, Zhang W. Association between polymorphisms in mannose-binding lectin 2 gene with pulmonary tuberculosis susceptibility. Hereditas. 2020; 3(1):33. doi: 101186/s41065-020-00146-w

27. van Asbeck EC, Hoepelman AI, Scharringa J, Herpers BL, Verhoef J. Mannose binding lectin plays a crucial role in innate immunity against yeast by enhanced complement activation and enhanced uptake of polymorphonuclear cells. BMC Microbiology. 2008;18(8):229. doi: 101186/1471-2180-8-229

28. Alonso DP, Ferreira AF, Ribolla PE, de Miranda Santos IK, do Socorro Pires e Cruz M, Aécio de Carvalho F, Abatepaulo AR, Lamounier Costa D, Werneck GL, Farias TJ, Soares MJ, Costa CH. Genotypes of the mannan-binding lectin gene and susceptibility to visceral leishmaniasis and clinical complications. The Journal of Infectious Diseases. 2007;15(8):1212-1217. doi: 101086/512683

29. Santos IK, Costa CH, Krieger H, Feitosa MF, Zurakowski D, Fardin B, Gomes RB, Weiner DL, Harn DA, Ezekowitz RA, Epstein JE. Mannan-binding lectin enhances susceptibility to visceral leishmaniasis. Infection and Immunity. 2001; 69(8):5212-5215. doi: 101128/IAI6985212-5215 2001